Please assess the completion status of the following clinical trial:

Trial Title: Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria (condensed):~* Multiple myeloma that is double-refractory to a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD) after at least 2 prior lines of therapy OR have failed at least 3 prior lines of therapy~* Measurable disease activity as indicated by serum or urine M-protein, serum free light chain, biopsy-proven plasmacytoma, \>5% bone marrow plasma cells.~* Adequate vital organ function as indicated by ANC (\>1000/uL), platelet count (\>50,000/uL), hemoglobin (\>8 g/dL), serum ALT and AST (each \<3.0 x upper limit of normal), total bilirubin (\<2 mg/dL), creatinine clearance (\>30 mL/min), and cardiac ejection fraction (\>45%)~Exclusion Criteria (condensed):~NOTE: Prior anti-BCMA or CAR-T therapy is NOT exclusionary~* Active plasma cell leukemia~* Pregnant or lactating~* Active, uncontrolled infection~* Active and severe auto-immune disease~* Active arrhythmia, or obstructive or restrictive pulmonary disease~* Central nervous system disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Descartes-08 plus fludarabine/cyclophosphamide pretreat (Type: EXPERIMENTAL): Autologous CD8+ T-cells transiently expressing an anti-BCMA chimeric antigen receptor

Based on this trial design, predict the completion outcome and termination type (if applicable).